Last Chance to Register! Creative Biolabs with Dr. Melita Irving Presents Live Webinar on Novel CAR-T Therapy

Chimeric antigen receptor T-cell (CAR T) therapies have demonstrated great potential as a new type of cancer treatment that uses the immune system to fight diseases. The scope to further optimize CAR-T cell design and delivery raises the hope of a cure for many more people with malignancies, and heralds an exciting new era in cancer treatment. That is why Creative Biolabs launched a webinar series focusing on CAR T/NK cell therapy to share the cutting-edge technology and information in this field, hoping to boost the development and discovery of better and safer therapies.

In the upcoming webinar, Creative Biolabs has invited Dr. Melita Irving to share the latest findings of her research team. Taking place as a fully live-streamed digital event at 10:00 AM, August 25, Eastern Daylight Time, this webinar is free to all registrants. Researchers, academics, and students working on CAR-T cells won’t want to miss out on this opportunity to deep dive into the communication with Dr. Melita.

Webinar Info

Subject: Engineering Strategies for Improving Adoptive T cell Therapy Against Cancer

Time & date: 10 AM EDT, August 25, 2022

Speaker Bio:

Dr. Melita Irving is the group leader of the human integrated tumor immunology discovery engine (Hi-TIDe) research group in the Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research. The research focus of her team is on the development of gene-engineered T cells, tailored to treat specific tumors, that enable or promote tumor-targeting, productive T-cell signaling and metabolic activity under suppressive conditions, tumor microenvironment re-programming to foster immunity and safety.

Key topics to be covered in this webinar:

  • The use of syngeneic tumor models to evaluate the ability of co-engineered murine CAR T cells to reprogram the tumor microenvironment and boost T cell function
  • The use of low-doses of irradiation to inflame cold tumors and render them responsive to rational combinatorial immunotherapy
  • The novel STOP-CAR to integrate efficacy and safety directly into chimeric antigen receptor design

For those who are not available in this period, registration is still open and an email notification will be sent containing the link to the webinar recording as soon as the event is available for on-demand viewing.

Looking for past webinars on CAR-T therapy? Check out on

About Creative Biolabs

With years of exploration in biotechnology, Creative Biolabs has gathered talented scientists working closely with worldwide partners to develop and produce medicines of tomorrow. Specifically, Creative Biolabs specializes in one-stop custom services for CAR-T therapy development, dendritic cell therapy development, TCR modified T cell development, CAR-macrophage therapy development, cancer vaccine development, etc.

Media Contact

Company Name
Creative Biolabs
Contact Name
Candy Swift
United States

comtex tracking


Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Ireland Daily News journalist was involved in the writing and production of this article.